06. Late adverse events occurred in 14% and 5.3%, respectively, p=0.44, with no severe adverse event. Curative resection rates were 67% and 63% for adenocarcinomas of the esophagus and the gastric cardia, respectively, p=0.89.

ESD is a safe treatment for T1 adenocarcinomas of the esophagogastric junction, curative in two thirds of the…[Read more]